Base de dados : MEDLINE
Pesquisa : E02.319.452 [Categoria DeCS]
Referências encontradas : 8689 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 869 ir para página                         

  1 / 8689 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29192092
[Au] Autor:den Heijer M; Bakker A; Gooren L
[Ad] Endereço:Department of internal medicine, VU Medical Center, Amsterdam, Netherlands m.denheijer@vumc.nl.
[Ti] Título:Long term hormonal treatment for transgender people.
[So] Source:BMJ;359:j5027, 2017 11 30.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Terapia de Reposição Hormonal/efeitos adversos
Terapia de Reposição Hormonal/utilização
Policitemia/induzido quimicamente
Pessoas Transgênero/psicologia
Trombose Venosa/induzido quimicamente
[Mh] Termos MeSH secundário: Adulto
Assistência ao Convalescente
Idoso
Antagonistas de Androgênios/farmacologia
Estrogênios/administração & dosagem
Estrogênios/farmacologia
Feminino
Disforia de Gênero/psicologia
Guias como Assunto
Seres Humanos
Masculino
Policitemia/complicações
Fatores de Risco
Testosterona/administração & dosagem
Testosterona/farmacologia
Tempo
Trombose Venosa/complicações
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androgen Antagonists); 0 (Estrogens); 3XMK78S47O (Testosterone)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171202
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.j5027


  2 / 8689 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29480822
[Au] Autor:Zhang Q; Zang L; Li YJ; Han BY; Gu WJ; Yan WH; Jin N; Chen K; Du J; Wang XL; Guo QH; Yang GQ; Yang LJ; Ba JM; Lv ZH; Dou JT; Lu JM; Mu YM
[Ad] Endereço:Department of Endocrinology, Chinese PLA General Hospital.
[Ti] Título:Thyrotrophic status in patients with pituitary stalk interruption syndrome.
[So] Source:Medicine (Baltimore);97(2):e9084, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Pituitary stalk interruption syndrome (PSIS) is associated with simultaneous or subsequent pituitary hormone deficiencies (PHDs). Although the clinical features of multiple PHDs are well known, the status of the thyrotrophic axis in PSIS has not been thoroughly investigated.The clinical data of 89 PSIS patients and 34 Sheehan syndrome (SS) patients were retrospectively analyzed.The prevalence of central hypothyroidism in the PSIS patients and the SS patients was 79.8% and 70.6%, respectively. The thyroid-stimulating hormone (TSH) levels in the PSIS patients were significantly higher in comparison with the SS patients (5.13 ±â€Š3.40 vs 1.67 ±â€Š1.20 mU/L, P < .05). TSH elevation (8.79 ±â€Š3.17 mU/L) was noticed in 29 of 71 (40.85%) hypothyroid PSIS patients but not in the 24 hypothyroid SS patients. The TSH levels in the hypothyroid PSIS patients were significantly higher in comparison with the euthyroid PSIS patients (5.42 ±â€Š3.67 vs 3.66 ±â€Š1.50 mU/L). Thyroid hormone replacement significantly reduced the TSH levels in the PSIS patients with elevated TSH levels from 7.24 ±â€Š0.98 to 1.67 ±â€Š1.51 mU/L (P < .05). The logistic regression analysis suggested that TSH level was not significantly associated with pituitary stalk status and height of the anterior pituitary gland.PSIS is a newly recognized cause of central hypothyroidism. The proportion and amplitude of TSH elevations are higher in PSIS than in other causes of central hypothyroidism.
[Mh] Termos MeSH primário: Doenças da Hipófise/metabolismo
Tireotropina/metabolismo
[Mh] Termos MeSH secundário: Adulto
Feminino
Terapia de Reposição Hormonal
Seres Humanos
Modelos Logísticos
Masculino
Meia-Idade
Doenças da Hipófise/diagnóstico por imagem
Doenças da Hipófise/tratamento farmacológico
Doenças da Hipófise/epidemiologia
Hipófise/diagnóstico por imagem
Hipófise/efeitos dos fármacos
Hipófise/metabolismo
Prevalência
Estudos Retrospectivos
Tireotropina/administração & dosagem
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
9002-71-5 (Thyrotropin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180227
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009084


  3 / 8689 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28471115
[Au] Autor:Mao XC; Yu WQ; Shang JB; Wang KJ
[Ad] Endereço:Department of Head and Neck Surgery, Zhejiang Cancer Hospital, Hangzhou 310011, China.
[Ti] Título:Clinical characteristics and treatment of thyroid cancer in children and adolescents: a retrospective analysis of 83 patients.
[So] Source:J Zhejiang Univ Sci B;18(5):430-436, 2017 May.
[Is] ISSN:1862-1783
[Cp] País de publicação:China
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To study the clinical characteristics, treatment, and prognosis of thyroid cancer in children and adolescents. METHODS: We performed a retrospective analysis of clinical data from 83 cases of thyroid cancer in children and adolescents from January 1990 to December 2010. We compared extra-thyroid extension, lymph node metastasis, distant metastasis, and prognosis between pediatric patients ≤12 years of age (27 cases) and those >12 years of age (56 cases). All the patients agreed to undergo thyroidectomy and endocrine therapy, and the consent was obtained from parents or guardians. RESULTS: Histopathology included papillary carcinoma in 67 cases, papillary carcinoma with partial follicular growth pattern in 1 case, papillary carcinoma with squamous metaplasia in 4 cases, follicular carcinoma in 7 cases, medullary carcinoma in 3 cases, and poorly differentiated carcinoma in 1 case. The total lymph node metastasis rate was 78.31%. Patients ≤12 years of age showed a higher rate of lymph node metastasis than the older group (92.59% vs. 71.43%, P=0.028). The incidence rate in females in the older group was higher than that in the younger group (80.36% vs. 59.26%, P=0.041). There were no significant differences in extra-thyroid extension, distant metastasis, survival rate, or recurrent disease between the two groups. CONCLUSIONS: The lymph node metastasis of thyroid cancer is higher in patients ≤12 years of age than in those >12 years of age; the incidence rate is higher in females than in males. Childhood thyroid cancer has a good prognosis, surgery being the most effective treatment. Choosing a reasonable surgery method and comprehensive postoperative treatment can achieve a cure and satisfactory survival rate.
[Mh] Termos MeSH primário: Terapia de Reposição Hormonal/mortalidade
Avaliação de Sintomas/métodos
Neoplasias da Glândula Tireoide/diagnóstico
Neoplasias da Glândula Tireoide/terapia
Tireoidectomia/mortalidade
[Mh] Termos MeSH secundário: Adolescente
Distribuição por Idade
Criança
Pré-Escolar
China/epidemiologia
Diagnóstico Diferencial
Feminino
Terapia de Reposição Hormonal/utilização
Seres Humanos
Lactente
Recém-Nascido
Metástase Linfática
Masculino
Prevalência
Fatores de Risco
Distribuição por Sexo
Taxa de Sobrevida
Neoplasias da Glândula Tireoide/mortalidade
Tireoidectomia/utilização
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1631/jzus.B1600308


  4 / 8689 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29443755
[Au] Autor:Cai X; Yu D; Xie Y; Zhou H
[Ad] Endereço:Department of Pediatrics, West China Second University Hospital.
[Ti] Título:Argininemia as a cause of severe chronic stunting and partial growth hormone deficiency (PGHD): A case report.
[So] Source:Medicine (Baltimore);97(7):e9880, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Argininemia is an autosomal recessive inherited disorder of the urea cycle. Because of its atypical symptoms in early age, diagnosis can be delayed until the typical chronic manifestations - including spastic diplegia, deterioration in cognitive function, and epilepsy - appear in later childhood. PATIENT CONCERNS: A Chinese boy initially presented with severe stunting and partial growth hormone deficiency (PGHD) at 3 years old and was initially treated with growth hormone replacement therapy. Seven years later (at 10 years old), he presented with spastic diplegia, cognitive function lesions, epilepsy, and peripheral neuropathy. DIAGNOSES: Ultimately, the patient was diagnosed with argininemia with homozygous mutation (c.32T>C) of the ARG1 gene at 10 years old. Blood tests showed mildly elevated blood ammonia and creatine kinase, and persistently elevated bilirubin. INTERVENTIONS: Protein intake was limited to 0.8 g/kg/day, citrulline (150-200 mg [kg d]) was prescribed. OUTCOMES: The patient's mental state and vomiting had improved after 3 months treatment. At 10 years and 9 month old, his height and weight had reached 121cm and 22kg, respectively, but his spastic diplegia symptoms had not improved. LESSONS: This case demonstrates that stunting and PGHD that does not respond to growth hormone replacement therapy might hint at inborn errors of metabolism (IEM). IEM should also be considered in patients with persistently elevated bilirubin with or without abnormal liver transaminase, as well as elevated blood ammonia and creatine kinase, in the absence of hepatic disease.
[Mh] Termos MeSH primário: Transtornos do Crescimento
Hiperargininemia
[Mh] Termos MeSH secundário: Arginase/genética
Bilirrubina/análise
Criança
Pré-Escolar
Diagnóstico Diferencial
Transtornos do Crescimento/diagnóstico
Transtornos do Crescimento/etiologia
Hormônio do Crescimento/análise
Hormônio do Crescimento/deficiência
Hormônio do Crescimento/uso terapêutico
Terapia de Reposição Hormonal/efeitos adversos
Terapia de Reposição Hormonal/métodos
Seres Humanos
Hiperargininemia/diagnóstico
Hiperargininemia/genética
Hiperargininemia/fisiopatologia
Hiperargininemia/terapia
Masculino
Mutação
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
9002-72-6 (Growth Hormone); EC 3.5.3.1 (Arginase); RFM9X3LJ49 (Bilirubin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180215
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009880


  5 / 8689 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29220342
[Au] Autor:Trimble JO; Light B
[Ad] Endereço:Humco Compounding, Austin, Texas.
[Ti] Título:Effect of Penetration Enhancers on the Percuaneous Delivery of Hormone Replacement Actives.
[So] Source:Int J Pharm Compd;21(6):530-535, 2017 Nov-Dec.
[Is] ISSN:1092-4221
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Transdermal compositions for hormone replacement are comprised of exogenous hormones that are biochemically similar to those produced endogenously by the ovaries or elsewhere in the body. In this work, estradiol, estriol, and testosterone were loaded in transdermal vehicles, prepared using one of three selected penetration enhancer mixtures: Vehicle 1 (olive oil and oleic acid), Vehicle 2 (isopropyl palmitate and lecithin), and Vehicle 3 (isopropyl myristate and lecithin). The influence of penetration enhancers on transdermal delivery was evaluated using Franz-type diffusion cells and Normal Human 3D Model of Epidermal Tissue. Results showed that drug delivery is affected by the penetration enhancer used in the transdermal composition.
[Mh] Termos MeSH primário: Terapia de Reposição Hormonal
Absorção Cutânea
[Mh] Termos MeSH secundário: Administração Cutânea
Cromatografia Líquida de Alta Pressão
Estradiol/administração & dosagem
Estradiol/química
Estradiol/farmacocinética
Seres Humanos
Permeabilidade
Solubilidade
Testosterona/administração & dosagem
Testosterona/química
Testosterona/farmacocinética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
3XMK78S47O (Testosterone); 4TI98Z838E (Estradiol)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171209
[St] Status:MEDLINE


  6 / 8689 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29334271
[Au] Autor:Corona G; Rastrelli G; Reisman Y; Sforza A; Maggi M
[Ad] Endereço:a Endocrinology Unit, Medical Department , Maggiore-Bellaria Hospital, Azienda-Usl Bologna , Bologna , Italy.
[Ti] Título:The safety of available treatments of male hypogonadism in organic and functional hypogonadism.
[So] Source:Expert Opin Drug Saf;17(3):277-292, 2018 Mar.
[Is] ISSN:1744-764X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: In the case of primary male hypogonadism (HG), only testosterone (T) replacement therapy (TRT) is possible whereas when the problem is secondary to a pituitary or hypothalamus alteration both T production and fertility can be, theoretically, restored. We here systematically reviewed and discussed the advantages and limits of medications formally approved for the treatment of HG. Areas covered: Data derived from available meta-analyses of placebo controlled randomized trials (RCTs) were considered and analyzed. Gonadotropins are well-toleratedand their use is mainly limited by higher costs and a more cumbersome treatment schedule than TRT. Available RCTs on TRT suggest that cardiovascular (CV) and venous thromboembolism risk is not a major issue and that prostate safety is guaranteed. The risk of increased hematocrit is mainly limited to the use of short terminjectable preparations. Expert opinion: In the last few years the concept of 'organic' irreversible HG and 'functional' or age- and comorbidity-related HG has been introduced. This definition is not evidence-based. The majority of RCTs enrolled patients with 'functional' HG. Considering the significant improvement in body composition, glucose metabolism and sexual activity, TRT should not be limited to 'organic' HG, but also offered for 'functional'.
[Mh] Termos MeSH primário: Gonadotropinas/administração & dosagem
Hipogonadismo/tratamento farmacológico
Testosterona/administração & dosagem
[Mh] Termos MeSH secundário: Gonadotropinas/efeitos adversos
Terapia de Reposição Hormonal/efeitos adversos
Terapia de Reposição Hormonal/métodos
Seres Humanos
Hipogonadismo/etiologia
Doenças Hipotalâmicas/complicações
Infertilidade Masculina/tratamento farmacológico
Infertilidade Masculina/etiologia
Masculino
Doenças da Hipófise/complicações
Ensaios Clínicos Controlados Aleatórios como Assunto
Testosterona/efeitos adversos
Testosterona/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Gonadotropins); 3XMK78S47O (Testosterone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180116
[St] Status:MEDLINE
[do] DOI:10.1080/14740338.2018.1424831


  7 / 8689 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29328563
[Au] Autor:Dragovic T; Duran Z; Jelic S; Marinkovic D; Kikovic S; Kuzmic-Jankovic S; Hajdukovic Z
[Ti] Título:Coexisting diseases modifying each other's presentation - lack of growth failure in Turner syndrome due to the associated pituitary gigantism.
[So] Source:Vojnosanit Pregl;73(10):961-6, 2016 Oct.
[Is] ISSN:0042-8450
[Cp] País de publicação:Serbia
[La] Idioma:eng
[Ab] Resumo:Introduction: Turner syndrome presents with one of the most frequent chromosomal aberrations in female, typically presented with growth retardation, ovarian insufficiency, facial dysmorphism, and numerous other somatic stigmata. Gigantism is an extremely rare condition resulting from an excessive growth hormone (GH) secretion that occurs during childhood before the fusion of epiphyseal growth plates. The major clinical feature of gigantism is growth acceleration, although these patients also suffer from hypogonadism and soft tissue hypertrophy. Case report: We presented a girl with mosaic Turner syndrome, delayed puberty and normal linear growth for the sex and age, due to the simultaneous GH hypersecretion by pituitary tumor. In the presented case all the typical phenotypic stigmata related to Turner syndrome were missing. Due to excessive pituitary GH secretion during the period while the epiphyseal growth plates of the long bones are still open, characteristic stagnation in longitudinal growth has not been demonstrated. The patient presented with delayed puberty and primary amenorrhea along with a sudden appearance of clinical signs of hypersomatotropinism, which were the reasons for seeking medical help at the age of 16. Conclusion: Physical examination of children presenting with delayed puberty but without growth arrest must include an overall hormonal and genetic testing even in the cases when typical clinical presentations of genetic disorder are absent. To the best of our knowledge, this is the first reported case of simultaneous presence of Turner syndrome and gigantism in the literature.
[Mh] Termos MeSH primário: Adenoma/complicações
Desenvolvimento do Adolescente
Estatura
Gigantismo/etiologia
Adenoma Hipofisário Secretor de Hormônio do Crescimento/complicações
Síndrome de Turner/complicações
[Mh] Termos MeSH secundário: Adenoma/sangue
Adenoma/fisiopatologia
Adenoma/cirurgia
Adolescente
Amenorreia/etiologia
Amenorreia/fisiopatologia
Biomarcadores/sangue
Feminino
Gigantismo/sangue
Gigantismo/fisiopatologia
Adenoma Hipofisário Secretor de Hormônio do Crescimento/sangue
Adenoma Hipofisário Secretor de Hormônio do Crescimento/fisiopatologia
Adenoma Hipofisário Secretor de Hormônio do Crescimento/cirurgia
Terapia de Reposição Hormonal
Hormônio do Crescimento Humano/sangue
Seres Humanos
Fator de Crescimento Insulin-Like I/metabolismo
Imagem por Ressonância Magnética
Mosaicismo
Puberdade Tardia/etiologia
Puberdade Tardia/fisiopatologia
Resultado do Tratamento
Síndrome de Turner/tratamento farmacológico
Síndrome de Turner/genética
Síndrome de Turner/fisiopatologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (IGF1 protein, human); 12629-01-5 (Human Growth Hormone); 67763-96-6 (Insulin-Like Growth Factor I)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180113
[St] Status:MEDLINE
[do] DOI:10.2298/VSP150620014D


  8 / 8689 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29406064
[Au] Autor:Sigalos JT; Pastuszak AW; Khera M
[Ad] Endereço:Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030, USA.
[Ti] Título:Hypogonadism: Therapeutic Risks, Benefits, and Outcomes.
[So] Source:Med Clin North Am;102(2):361-372, 2018 Mar.
[Is] ISSN:1557-9859
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Hypogonadism is a common condition defined by the presence of low serum testosterone levels and hypogonadal symptoms, and most commonly treated using testosterone therapy (TTh). The accuracy of diagnosis and appropriateness of treatment, along with proper follow-up, are increasingly important given the large increase in testosterone prescriptions and the recent concern for cardiovascular (CV) risk associated with TTh. In March of 2015, the US Food and Drug Administration required that testosterone product labels disclose a potential CV risk, despite the evidence base for this association being weak and inconclusive. However, TTh may improve CV outcomes rather than increase risks.
[Mh] Termos MeSH primário: Hipogonadismo/tratamento farmacológico
Testosterona/deficiência
Testosterona/uso terapêutico
[Mh] Termos MeSH secundário: Doenças Cardiovasculares/induzido quimicamente
Doenças Cardiovasculares/etiologia
Terapia de Reposição Hormonal/efeitos adversos
Seres Humanos
Hipogonadismo/diagnóstico
Masculino
Medição de Risco
Fatores de Risco
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
3XMK78S47O (Testosterone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180207
[St] Status:MEDLINE


  9 / 8689 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27770281
[Au] Autor:Indini A; Schiavello E; Biassoni V; Bergamaschi L; Magni MC; Puma N; Chiaravalli S; Pallotti F; Seregni E; Diletto B; Pecori E; Gandola L; Poggi G; Massimino M
[Ad] Endereço:Pediatric Oncology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Via Venezian 1, 20133, Milan, Italy. alice.indini@istitutotumori.mi.it.
[Ti] Título:Long-term safety of growth hormone replacement therapy after childhood medulloblastoma and PNET: it is time to set aside old concerns.
[So] Source:J Neurooncol;131(2):349-357, 2017 01.
[Is] ISSN:1573-7373
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:To assess the long-term safety of administering growth hormone (GH) in patients with GH deficiency due to treatment for childhood medulloblastoma and primitive neuroectodermal tumor (PNET). Data were retrospectively retrieved on children receiving GH supplementation, assessing their disease-free and overall survival outcomes and risk of secondary malignancies using Kaplan-Meier and Cox models. Overall 65 children were consecutively collected from May 1981 to April 2013. All patients had undergone craniospinal irradiation (total dose 18-39 Gy), and subsequently received GH for a median (interquartile range, IQR) of 81 (50.6-114.9) months. At a median (IQR) of 122.4 months (74.4-149.5) after the end of their adjuvant cancer treatment, two patients (3 %) experienced recurrent disease and 8 (12.3 %) developed secondary malignancies, all but one of them (an osteosarcoma) related to radiation exposure and occurring within the radiation fields. There was no apparent correlation between the administration of GH replacement therapy (or its duration) and primary tumor relapse or the onset of secondary malignancies [HR: 1.01 (95 % CI: 0.98, 1.03) for every additional 12 months of GH supplementation; p = 0.36). At univariate analysis, the large cell or anaplastic medulloblastoma subtype, metastases and myeloablative chemotherapy correlated with a higher risk of secondary malignancies (p < 0.1), but multivariate analysis failed to identify any factors independently associated with this risk. Our data supports once more the safety of long-term GH replacement therapy in children treated for medulloblastoma/PNET, previously reported in larger data sets. The neurooncology community now need to warrant large-scale meta-analyses or international prospective trials in order to consolidate our knowledge of factors other than GH, such as genetic predisposition, high-grade/metastatic disease, high-dose chemotherapy and era of treatment, in promoting the occurrence of secondary malignancies.
[Mh] Termos MeSH primário: Neoplasias Encefálicas/tratamento farmacológico
Hormônio do Crescimento/efeitos adversos
Terapia de Reposição Hormonal/efeitos adversos
Meduloblastoma/tratamento farmacológico
Tumores Neuroectodérmicos Primitivos/tratamento farmacológico
[Mh] Termos MeSH secundário: Criança
Feminino
Hormônio do Crescimento/uso terapêutico
Seres Humanos
Estimativa de Kaplan-Meier
Masculino
Estudos Retrospectivos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
9002-72-6 (Growth Hormone)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180119
[Lr] Data última revisão:
180119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161023
[St] Status:MEDLINE
[do] DOI:10.1007/s11060-016-2306-7


  10 / 8689 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28740585
[Au] Autor:Goodale T; Sadhu A; Petak S; Robbins R
[Ad] Endereço:Houston Methodist Hospital, Houston, Texas.
[Ti] Título:Testosterone and the Heart.
[So] Source:Methodist Debakey Cardiovasc J;13(2):68-72, 2017 Apr-Jun.
[Is] ISSN:1947-6108
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Testosterone (T) has a number of important effects on the cardiovascular system. In men, T levels begin to decrease after age 40, and this decrease has been associated with an increase in all-cause mortality and cardiovascular (CV) risk. Low T levels in men may increase their risk of developing coronary artery disease (CAD), metabolic syndrome, and type 2 diabetes. Reduced T levels in men with congestive heart failure (CHF) portends a poor prognosis and is associated with increased mortality. Studies have reported a reduced CV risk with higher endogenous T concentration, improvement of known CV risk factors with T therapy, and reduced mortality in T-deficient men who underwent T replacement therapy versus untreated men. Testosterone replacement therapy (TRT) has been shown to improve myocardial ischemia in men with CAD, improve exercise capacity in patients with CHF, and improve serum glucose levels, HbA1c, and insulin resistance in men with diabetes and prediabetes. There are no large long-term, placebo-controlled, randomized clinical trials to provide definitive conclusions about TRT and CV risk. However, there currently is no credible evidence that T therapy increases CV risk and substantial evidence that it does not. In fact, existing data suggests that T therapy may offer CV benefits to men.
[Mh] Termos MeSH primário: Doenças Cardiovasculares/sangue
Sistema Cardiovascular/metabolismo
Testosterona/sangue
[Mh] Termos MeSH secundário: Doenças Cardiovasculares/tratamento farmacológico
Doenças Cardiovasculares/epidemiologia
Doenças Cardiovasculares/fisiopatologia
Sistema Cardiovascular/efeitos dos fármacos
Sistema Cardiovascular/fisiopatologia
Feminino
Terapia de Reposição Hormonal
Seres Humanos
Masculino
Recuperação de Função Fisiológica
Fatores de Risco
Testosterona/deficiência
Testosterona/uso terapêutico
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
3XMK78S47O (Testosterone)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180116
[Lr] Data última revisão:
180116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170726
[St] Status:MEDLINE
[do] DOI:10.14797/mdcj-13-2-68



página 1 de 869 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde